Answers are grounded in this paper and cite their sources.
To elucidate the molecular mechanism by which xanthohumol (XN) alleviates rheumatoid arthritis (RA), this study integrated network pharmacology prediction, proteomic screening, and molecular dynamics simulation to systematically evaluate the inhibitory effects and targets of XN in TNF-α-induced fibroblast-like synoviocytes (MH7A cells). XN dose-dependently reversed the pathological proliferation and invasive behavior of MH7A cells and down-regulated pro-inflammatory cytokines such as IL-1β and IL-6, as well as fibrosis/angiogenesis-related factors including TGF-β1 and VEGF. Cross-validation of network pharmacology and proteomics indicated that these effects were closely associated with the inhibition of the p38/MAPK pathway, modulating inflammatory signal transduction to exert anti-RA effects. Molecular docking revealed that XN bound to the ATP-binding pocket of p38α kinase with an optimal binding energy of −7.623 kcal/mol, forming a stable hydrogen-bond network and hydrophobic stacking with the P-loop, hinge region, and catalytic residue Lys53. Molecular dynamics simulation (100 ns) combined with MM/GBSA analysis (ΔGbind = −104.14 kcal/mol) showed that the complex conformation was highly convergent, with significantly reduced RMSF of key residues in the catalytic domain, suggesting that XN induces rigidification of the kinase catalytic domain by stably occupying the ATP site, thereby blocking its phosphotransfer activity. Collectively, these results demonstrate that XN targets p38α kinase to inhibit the p38/MAPK pathway, intervening in RA pathological progression at multiple levels and providing experimental evidence for its anti-RA molecular mechanism.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: